← Back to Screener
Zura Bio Limited Class A Ordinary Shares (ZURA)
Price$5.37
Favorite Metrics
Price vs S&P 500 (26W)32.23%
Price vs S&P 500 (4W)-11.73%
Market Capitalization$491.42M
All Metrics
Book Value / Share (Quarterly)$1.38
P/TBV (Annual)1.38x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.88
Price vs S&P 500 (YTD)-1.45%
EPS (TTM)$-0.72
10-Day Avg Trading Volume0.63M
EPS Excl Extra (TTM)$-0.72
EPS (Annual)$-0.72
ROI (Annual)-35.69%
Cash / Share (Quarterly)$1.48
ROA (Last FY)-29.19%
EBITD / Share (TTM)$-0.80
Cash Flow / Share (Annual)$-0.51
P/B Ratio4.84x
P/B Ratio (Quarterly)3.36x
Net Income / Employee (Annual)$-2
ROA (TTM)-46.12%
EPS Incl Extra (Annual)$-0.72
Current Ratio (Annual)9.16x
Quick Ratio (Quarterly)8.82x
3-Month Avg Trading Volume0.66M
52-Week Price Return336.59%
EV / Free Cash Flow (Annual)52.05x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.47
52-Week High$7.44
EPS Excl Extra (Annual)$-0.72
26-Week Price Return39.12%
Quick Ratio (Annual)9.04x
13-Week Price Return14.50%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)9.05x
Enterprise Value$382.008
Revenue / Employee (Annual)$0
Cash / Share (Annual)$2.70
3-Month Return Std Dev85.80%
Net Income / Employee (TTM)$-2
ROE (Last FY)-35.69%
EPS Basic Excl Extra (Annual)$-0.72
EV / Free Cash Flow (TTM)156.06x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.72
ROI (TTM)-57.24%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$7.75
Price vs S&P 500 (52W)301.95%
Year-to-Date Return2.48%
5-Day Price Return-6.12%
EPS Normalized (Annual)$-0.72
Month-to-Date Return-9.75%
Cash Flow / Share (TTM)$0.03
EBITD / Share (Annual)$-0.80
LT Debt / Equity (Annual)0.00x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.72
P/TBV (Quarterly)2.92x
P/B Ratio (Annual)1.11x
Book Value / Share (Annual)$2.25
Price vs S&P 500 (13W)12.12%
Beta0.11x
Revenue / Share (TTM)$0.00
ROE (TTM)-57.24%
52-Week Low$0.98
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.31
4.31
4.36
4.36
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ZURAZura Bio Limited Class A Ordinary Shares | — | — | — | — | $5.37 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 11.09x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Zura Bio Ltd is a clinical-stage immunology company developing novel dual-pathway antibodies to treat autoimmune and inflammatory diseases. The company has three lead programs that have completed Phase I/Ib studies and are advancing to Phase II trials. Its pipeline includes tibulizumab and torudokimab, which are being evaluated for efficacy, safety, and dosing convenience across multiple therapeutic indications.